Strontium-89 therapy for painful osseous metastases: Activity-response relationship
- Univ. of Cincinnati, OH (United States)
An activity (dose) escalation study of Sr-89 in 63 evaluable patients with painful bone metastases was performed to determine if there were clinical benefits to higher administered activities. All had a positive bone scan at the painful site. The administered activity ranged from 16 to 80 uCi/kg. The data were examined by regression analysis and Student`s t test to detect relationships between the activity administered and clinical response, time to response and response duration. There was no statistically significant relationship between activity administered and pain reduction over the range from 16-80 uCi/kg. In the lower third of activities administered (16-37 uCi/kg) the response rate was 13/20, 65%; in the upper third range, 55-80 uCi/kg, the response rate was 12 of 18, 67%. Time to response was not statistically associated with dose (p=0.10) but duration of response was correlated with dose (p=0.04). In summary, patient response to Sr-89 for pain reduction does not increase with increasing activities from 16-80 uCi/kg. Duration of response, but not time to response, correlated with the activity given.
- OSTI ID:
- 197908
- Report Number(s):
- CONF-940605-; ISSN 0161-5505; TRN: 95:007029-0039
- Journal Information:
- Journal of Nuclear Medicine, Vol. 35, Issue Suppl.5; Conference: 41. annual meeting of the Society of Nuclear Medicine, Orlando, FL (United States), 5-8 Jun 1994; Other Information: PBD: May 1994
- Country of Publication:
- United States
- Language:
- English
Similar Records
Tin-117m(4+)-DTPA for palliation of pain from osseous metastases: A pilot study
The palliation of osseous metastasis with sup 32 P or sup 89 Sr compared with external beam and hemibody irradiation: A historical perspective